SOURCE: American Diabetes Association
ALEXANDRIA, VA and INDIANAPOLIS, IN--(Marketwired - Dec 17, 2013) - The American Diabetes Association (Association) and Eli Lilly and Company are pleased to announce the recipients of the American Diabetes Association and Lilly Clinical Research Award: Diabetes Care in Older Adults, a three-year collaborative research program aimed at better understanding diabetes care in older adults. The program, made possible through $1.2 million in funding from Lilly Diabetes, is awarding two clinical grants that will be directed, managed, and overseen by the Association.
"The American Diabetes Association is thrilled to join with Eli Lilly and Company to award the American Diabetes Association and Lilly Clinical Research Award: Diabetes Care in Older Adults research grants," said John E. Anderson, MD, president, medicine & science, American Diabetes Association. "Through their innovative research, the recipients of these awards will help improve our understanding of the goals, barriers, and effects of treatments and interventions in the older adult population with diabetes."
It is currently estimated that approximately 25 percent of people aged 65 and older in the U.S. have diabetes and the prevalence is expected to grow as the population ages. Diabetes in older adults can lead to increases in morbidity (including the characteristic complications of diabetes), decreased functional and mental status, and reduced life expectancy.1 While substantial evidence exists that lowering blood glucose, blood pressure, and cholesterol can reduce the risk of diabetes complications, older adults have often been excluded from or under-represented in studies that led to this evidence. The aim of this research initiative is to identify the safest and most effective means of addressing diabetes management in older adults.
"The number of people affected by diabetes is increasing, and people are living longer with the disease, so it's particularly important to investigate new ways in which to manage an ever more diverse population with diabetes," said Robert Heine, vice president, medical affairs, Lilly Diabetes. "We're very pleased to collaborate with the Association on this area of high need and congratulate the grant recipients on these research awards. Along with the entire diabetes community, we look forward to seeing the results of this work in the coming years."
The grants will be three-year awards starting in early 2014. The award recipients are:
- Guillermo E. Umpierrez, MD, of Emory University School of Medicine, located in Atlanta. With this grant, Umpierrez will conduct a randomized controlled study, which will compare a DPP4 inhibitor (linagliptin) and a basal insulin (glargine) in long-term care residents who have type 2 diabetes.
- Dennis T. Villareal, MD, of the Biomedical Research Institute of New Mexico (BRINM), located in Albuquerque. Villareal's research will investigate a lifestyle intervention strategy to treat diabetes in older adults.
Throughout the years, the Association has funded innovative and groundbreaking diabetes research and has invested approximately $640 million in nearly 4,000 research projects. The Association's research allows people to lead healthier and more productive lives every day.
About the American Diabetes Association
The American Diabetes Association is leading the fight to Stop Diabetes® and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and our continued commitment to providing real solutions -- from medicines to support programs and more -- to make lives better. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
1American Diabetes Association, May 2013.
LD88298 12/2013 ©Lilly USA, LLC 2013. All rights reserved.